RxDoctor Payments Data

Thomas Gehlbach, MD

Pulmonary Disease · Madison, WINPI 1891905600

Payments from drug & device makers

$503in general payments, 2019–2025

Across 34 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$179
  • Boehringer Ingelheim$74
  • GSK$58
  • AstraZeneca$45
  • Grifols USA, LLC$45
  • Mylan Specialty L.p.$25
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$503 in reported general payments places this provider in the 40th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$124,981
Medicare patients
613
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter370$263,304
Breo ElliptaFluticasone/Vilanterol128$57,286
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr80$46,648
Dupixent PenDupilumab11$42,976
Spiriva RespimatTiotropium Bromide63$34,170
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$31,019
Pirfenidone14$25,627
Incruse ElliptaUmeclidinium Bromide51$25,334
Posaconazole16$20,287
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$17,201
Fluticasone-SalmeterolFluticasone Propion/Salmeterol92$13,469
Combivent RespimatIpratropium/Albuterol Sulfate14$11,758
SymbicortBudesonide/Formoterol Fumarate35$10,114
Advair HfaFluticasone Propion/Salmeterol18$8,858
Roflumilast50$7,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$58$399,639643 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$74$76,946133 claims
AstraZenecaBreztri Aerosphere, Symbicort$45$27,31561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →